Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a double-blind, randomized, multi-center, II/III study in at least 606 patients with advanced colorectal cancer. The study is being conducted to evaluate the safety of HR070803 combined with oxaliplatin, 5-FU/LV and bevacizumab in phase II and to evaluate the efficacy of HR070803 in combination with oxaliplatin, 5-FU/LV, and bevacizumab versus HR070803 simulator in combination with FOLFOX and bevacizumab for first-line treatment of patients with unresectable metastatic colorectal cancer.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HR070803 | Experimental | HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab |
|
| HR070803 simulator | Placebo Comparator | HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab | Drug | HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 8-12 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first) |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse Events (AE) According to NCI-CTCAE v5.0（Phase II） | An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant after signing the informed consent form and which does not necessarily have to have a causal relationship with this treatment. An AE could be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change infrequency and/or intensity) of a preexisting condition that is temporally associated with the use of study treatment, is also an AE. | From Baseline to primary completion date, about 48 months |
| Serious Adverse Events (SAE)（Phase II） | An SAE is defined as any of the following adverse events in a participant or clinical investigation participant after signing the informed consent form and which does not necessarily have to have a causal relationship with this treatment: events that result in death, life-threatening events; events requiring hospitalization or prolonged hospitalization; events leading to permanent or severe disability/loss of function (significant impairment of the ability to carry out normal life functions); congenital abnormalities or birth defects; a medically important event or intervention may be required to prevent any of these outcomes. | From Baseline to primary completion date, about 48 months |
| Progression-Free Survival (PFS) Assessed by IRC（Phase III） | from randomization to PD or death from any cause | From Baseline to primary completion date, about 48 months |
| Measure | Description | Time Frame |
|---|---|---|
| Overall Response Rate (ORR) Assessed by investigator（Phase II） | The proportion of patients who acquired complete response and partial response during treatment. | From Baseline to primary completion date, about 48 months |
| Disease Control Rate (DCR) by investigator（Phase II） |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sun Yat-Sen University Cancer Center | Guangzhou | Guangdog | 510060 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab | Drug | HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 8-12 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first) |
|
The proportion of patients who acquired complete response and partial response and stable disease during treatment. |
| From Baseline to primary completion date, about 48 months |
| Duration of Overall Response (DoR) by investigator（Phase II） | For subjects who demonstrated CR or PR, response duration is defined as the time from the date of first response (CR or PR) until the date of first documented disease progression or death. | From Baseline to primary completion date, about 48 months |
| Progression-Free Survival (PFS) Assessed by investigator（Phase II） | from randomization to PD or death from any cause. | From Baseline to primary completion date, about 48 months |
| Overall Survival (OS)（Phase II） | from randomization to death from any cause. | From Baseline to primary completion date, about 48 months |
| Characterize the PK（Phase II） | Serum concentrations of SN-38 and CPT-11 will be monitored. PK modeling will be performed and an appropriate model will be selected to describe the data. | From Baseline to primary completion date, about 48 months |
| Overall Survival (OS)（Phase III） | from randomization to death from any cause. | From Baseline to primary completion date, about 48 months |
| Progression-Free Survival (PFS) Assessed by investigator（Phase III） | from randomization to PD or death from any cause. | From Baseline to primary completion date, about 48 months |
| Overall Response Rate (ORR) Assessed by IRC and investigator（Phase III） | The proportion of patients who acquired complete response and partial response during treatment. | From Baseline to primary completion date, about 48 months |
| Duration of Overall Response (DoR) by IRC and investigator（Phase III） | For subjects who demonstrated CR or PR, response duration is defined as the time from the date of first response (CR or PR) until the date of first documented disease progression or death. | From Baseline to primary completion date, about 48 months |
| Disease Control Rate（DCR） by IRC and investigator（Phase III） | The proportion of patients who acquired complete response and partial response and stable disease during treatment. | From Baseline to primary completion date, about 48 months |
| Adverse Events (AE) According to NCI-CTCAE v5.0（Phase III） | An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant after signing the informed consent form and which does not necessarily have to have a causal relationship with this treatment. An AE could be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change infrequency and/or intensity) of a preexisting condition that is temporally associated with the use of study treatment, is also an AE. | From Baseline to primary completion date, about 48 months |
| Serious Adverse Events (SAE)（Phase III） | An SAE is defined as any of the following adverse events in a participant or clinical investigation participant after signing the informed consent form and which does not necessarily have to have a causal relationship with this treatment: events that result in death; life-threatening events; events requiring hospitalization or prolonged hospitalization; events leading to permanent or severe disability/loss of function (significant impairment of the ability to carry out normal life functions); congenital abnormalities or birth defects; a medically important event or intervention may be required to prevent any of these outcomes. | From Baseline to primary completion date, about 48 months |
| ID | Term |
|---|---|
| D015179 | Colorectal Neoplasms |
| ID | Term |
|---|---|
| D007414 | Intestinal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
| D012002 | Rectal Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077150 | Oxaliplatin |
| D000068258 | Bevacizumab |
| ID | Term |
|---|---|
| D056831 | Coordination Complexes |
| D009930 | Organic Chemicals |
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
Not provided
Not provided